Colorectal Adenocarcinoma
105
20
33
29
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
16 trials with published results (15%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.2%
16 terminated out of 105 trials
64.4%
-22.1% vs benchmark
4%
4 trials in Phase 3/4
55%
16 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (105)
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Evaluation of Skin Tests in Biotherapy Allergies
ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Study Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG).
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Early Onset Colorectal Cancer Detection